Table I. Baseline Clinical Characteristics (Safety Population)

	Placebo (n=326)	Donepezil (n=648)
Strokes/TIAs		
Strokes	207 (63.5)	429 (66.2)
No. of strokes, mean±SE, median (range)	0.9±0.1, 1.0 (0–4)	1.0±0.0, 1.0 (0–9)
Strokes before onset of dementia, n (%)	173 (53.1)	347 (53.5)
No. of strokes, mean±SE, median (range)	0.7±0.0, 1.0 (0–3)	0.7±0.0, 1.0 (0–6)
Months since first stroke, mean±SE, median (range)	66.6±5.1, 42.0 (1–367)	70.5±4.2, 45.5 (1–798)
Months since most recent stroke, mean±SE, median (range)	46.8±4.0, 25.0 (1–367)	48.4±3.0, 27.0 (0–508)
TIAs	106 (32.5)	201 (31.0)
No. of TIAs, mean±SE, median (range)	0.8±0.1, 0.0 (0–26)	0.8±0.1, 0.0 (0–14)
TIAs before onset of dementia, n (%)	67 (20.6)	139 (21.5)
No. of TIAs, mean±SE, median (range)	0.4±0.1, 0.0 (0–20)	0.4±0.1, 0.0 (0–12)
Months since first TIA, mean±SE, median (range)	59.0±6.0, 41.5 (0–332)	65.2±4.6, 46.5 (1–308)
Months since most recent TIA, mean±SE, median (range)	34.5±3.9, 16.0 (0–234)	40.3±3.8, 27.0 (0–287)
Elements that contributed to the diagnosis of VaD in this patient, n (%)		
Dementia onset		
Sudden, temporally related to known vascular event	192 (58.9)	367 (56.6)
Sudden, temporally unrelated to known vascular event	41 (12.6)	85 (13.1)
Gradual	93 (28.5)	192 (29.6)
Dementia progression		
Stepwise decline or fluctuating course (admixed with improvement)	276 (84.7)	541 (83.5)
Insidious, constant decline	48 (14.7)	94 (14.5)
Memory		
Memory deficit present but not most prominent feature of the dementia	156 (47.9)	291 (44.9)
Memory deficit most prominent feature of the dementia	170 (52.1)	353 (54.5)
Executive dysfunction (onset)		
Mild dysfunction, early in the course of dementia	271 (83.1)	521 (80.4)
Severe dysfunction, early in the course of dementia	41 (12.6)	97 (15.0)
Severe dysfunction, late in the course of dementia	9 (9.8)	20 (3.1)
Dementia subtype		
Subcortical	130 (39.9)	268 (41.4)
Cortical	51 (15.6)	104 (16.0)
Both subcortical and cortical	145 (44.5)	272 (42.0)
Neurologic exam		
Focal deficits present when dementia was diagnosed	212 (65.0)	421 (65.0)
Focal deficits subtle or absent when dementia was diagnosed	112 (34.4)	217 (33.5)
Neuroimaging when dementia diagnosed		
Infarcts of white matter lesions present	312 (95.7)	612 (94.4)
Normal (excluding atrophy)	4 (1.2)	8 (1.2)
Not done or unavailable	10 (3.1)	21 (3.7)
Gait disturbances (unsteadiness, frequent and unprovoked falls, other gait disturbance)		
Early in the course of disease	120 (36.8)	274 (42.3)
Late in the course of disease	16 (4.9)	32 (4.9)
No relevant gait disturbance	184 (56.4)	328 (50.6)
Not applicable (eg, patient nonambulatory)	4 (1.2)	9 (1.4)

(*Continued*)

Table I. Continued

	Placebo (n=326)	Donepezil (n=648)
Urinary symptoms (frequency, urgency, and/or nocturia)		
Early in the course of disease	62 (19.0)	97 (15.0)
Late in the course of disease	16 (4.9)	35 (5.4)
No relevant urinary symptoms	184 (56.4)	490 (75.6)
Not applicable (eg, indwelling catheter)	4 (1.2)	22 (3.4)
Vascular history (risk)		
Vascular risk factors present (hypertension, diabetes, etc)	298 (91.4)	578 (89.2)
No vascular risk factors on history	28 (8.6)	66 (10.2)
Vascular history (infarctions)		
History of TIAs or stroke(s)	231 (82.8)	522 (75.1)
No history of TIAs or stroke(s)	46 (16.5)	171 (24.6)
Pseudobulbar palsy		
Present	19 (5.8)	51 (7.9)
Absent	307 (94.2)	593 (91.5)
Personality/mood changes		
Present, likely of subcortical origin	201 (61.7)	358 (55.2)
No change compared with predemented state	125 (38.3)	286 (44.1)
Clinical characteristics		
Smoking (current)	31 (9.5)	69 (10.6)
DAT inventory total score (range, 1–18), mean±SE*	11.13±0.12	11.04±0.09
Concomitant medications used by at least 10% of patients in either group, %		
Agents acting on the renin-angiotensin system	49.1	46.6
Analgesics	17.2	15.0
Antithrombotic agents	82.2	74.5
β-Blocking agents	28.8	24.7
Calcium channel blockers	22.1	25.5
Cardiac therapy	16.9	15.4
Diuretics	31.0	30.4
Drugs for diabetes treatment	14.7	14.5
Serum lipid–reducing agents	40.5	39.4
Thyroid therapy	11.7	10.6

TIA indicates transient ischemic attack; and DAT, dementia of the Alzheimer type.

*Because this rating scale has items that can take a "not applicable" value, a mean of the "applicable" items is used rather than a total score. The overall mean score is calculated as 100 times *P*, where *P* indicates the average tendency for the patient to score between the lowest and highest score among the applicable transformed items. A higher score indicates better performance.

Table II. Primary and Secondary Outcome Measures Stratified by Scheltens' Scores

	V-ADAS-cog				NCT			
	NH		HA		NH		HA	
	Difference in LS Mean Δ (±SE)	*P*	Difference in LS Mean Δ (±SE)	*P*	Difference in LS Mean Δ (±SE)	*P*	Difference in LS Mean Δ (±SE)	*P*
Week 6*	−0.652 (0.44)	0.20	−0.457 (0.53)	0.42	−0.146 (0.10)	0.20	−0.060 (0.10)	0.58
Week 12*	−0.445 (0.47)	0.41	−2.221 (0.62)	<0.01	−0.206 (0.10)	0.07	−0.094 (0.09)	0.35
Week 18*	−0.286 (0.50)	0.62	−2.434 (0.70)	<0.01	−0.108 (0.10)	0.32	−0.094 (0.09)	0.33
Week 24*	−1.193 (0.60)	0.09	−2.265 (0.78)	<0.01	−0.189 (0.12)	0.16	−0.120 (0.10)	0.27
End point†	−1.303 (0.55)	0.04	−2.003 (0.71)	0.01	−0.188 (0.11)	0.12	−0.076 (0.09)	0.46
	Baseline LS Mean (±SE)		Baseline LS Mean (±SE)		Baseline LS Mean (±SE)		Baseline LS Mean (±SE)	
Placebo	18.05 (0.94)		23.89 (1.13)		2.62 (0.13)		3.19 (0.11)	
Donepezil	16.95 (0.75)		23.12 (0.83)		2.74 (0.10)		3.11 (0.08)	
	Baseline to End Point Δ LS Mean (±SE)		Baseline to End Point Δ LS Mean (±SE)		Baseline to End Point Δ LS Mean (±SE)		Baseline to End Point Δ LS Mean (±SE)	
Placebo	−0.80 (0.53)		1.44 (0.67)		−0.26 (0.10)		−0.02 (0.09)	
Donepezil	−2.11 (0.42)		−0.56 (0.50)		−0.45 (0.08)		−0.10 (0.07)	

	CIBIC-Plus				DAD			
	NH		HA		NH		HA	
	Difference in Percentage With Improvement‡	*P*	Difference in Percentage With Improvement	*P*	Difference in LS Mean Δ (±SE)	*P*	Difference in LS Mean Δ (±SE)	*P*
Week 6*	7.9	0.40	0.3	0.84				
Week 12*	14.8	0.03	6.3	0.76				
Week 18*	12.7	0.03	9.9	0.17				
Week 24*	15.8	0.10	10.3	0.19	2.822 (1.33)	0.07	1.985 (1.60)	0.25
End point	14.5	0.10	7.2	0.43	3.288 (1.25)	0.02	1.878 (1.60)	0.28
	Baseline Mean		Baseline Mean		Baseline LS Mean (±SE)		Baseline LS Mean (±SE)	
Placebo	3.32		3.67		75.82 (2.08)		67.37 (2.21)	
Donepezil	3.38		3.69		78.04 (1.64)		70.45 (1.68)	
	Percentage With Improvement From Baseline		Percentage With Improvement From Baseline		Baseline to End Point Δ LS Mean (±SE)		Baseline to End Point Δ LS Mean (±SE)	
Placebo	29.7		21.3		0.07 (1.19)		−0.94 (1.46)	
Donepezil	44.2		28.5		3.36 (0.93)		0.94 (1.11)	

	ADAS-cog			
	NH		HA	
	Difference in LS Mean Δ (±SE)	*P*	Difference in LS Mean Δ (±SE)	*P*
Week 6*	−0.245 (0.72)	0.57	−0.699 (0.44)	0.14
Week 12*	−0.347 (0.42)	0.47	−1.906 (0.53)	<0.01
Week 18*	0.013 (0.47)	0.98	−2.139 (0.60)	<0.01
Week 24*	−1.107 (0.47)	0.06	−1.522 (0.65)	0.04
End point	−1.201 (0.47)	0.03	−1.249 (0.60)	0.06
	Baseline LS Mean (±SE)		Baseline LS Mean (±SE)	
Placebo	15.40 (0.85)		20.47 (1.02)	
Donepezil	14.22 (0.68)		19.46 (0.76)	
	Baseline to End Point Δ LS Mean (±SE)		Baseline to End Point Δ LS Mean (±SE)	
Placebo	−0.73 (0.45)		0.54 (0.56)	
Donepezil	−1.93 (0.36)		−0.71 (0.42)	

LS indicates least squares; NH, normal hippocampal size; HA, hippocampal atrophy; NCT, Number Cancelation test. .

*Observed cases.

†ITT.

‡Sum of minimal, moderate, and marked improvement (the *P* value is based on the difference in the overall distribution, according to the Cochran-Mantel-Haenszel test).